Everything below concerns Intranasal route. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-02-01. Numbers and descriptions here follow the published literature rather than marketing material.
Proposed mechanisms center on modulation of the GABA system, but no single molecular target has been confirmed. Rodent studies report changes in GABA-A receptor expression and in the turnover of serotonin, dopamine, and norepinephrine in several brain regions. Increases in brain-derived neurotrophic factor and its receptor have also been described after repeated administration. These findings come largely from animal models, and the degree to which they describe human neurochemistry remains an open question. The mechanism is best characterized as multi-system and not fully resolved.
Pharmacokinetic data are limited. Like most short peptides, Selank is vulnerable to plasma and tissue peptidases, and its measured half-life in circulation is short, on a minutes scale. The Pro-Gly-Pro tail slows this degradation but does not eliminate it. Intranasal administration is the route described in most reports, with absorption through the nasal mucosa and a hypothesized path into the central nervous system that avoids the blood-brain barrier. Direct measurements of human brain exposure are unavailable, so distribution claims rest on inference from animal work.
Clinical evidence comes mainly from small studies conducted in Russia, several of which were open-label or lacked robust blinding. Reported outcomes include lower anxiety scores, changes in attention measures, and effects on asthenic states following illness. Sample sizes are typically in the tens of participants, and independent replication outside the region is scarce. Reviews published in English generally note the limited methodological quality of the underlying trials. Whether the compound produces clinically meaningful effects under rigorous conditions remains unresolved.
Selank is a synthetic heptapeptide developed in Russia. Its sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, a seven-residue chain built around the natural tetrapeptide tuftsin. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences first described the compound in the mid-1990s. The design combined the tuftsin core with an added Pro-Gly-Pro tail, a modification intended to extend the molecule's stability in biological fluids. Published work on the peptide has appeared mainly in Russian-language journals.
Reported activity for Selank centers on anxiolytic and nootropic effects. Russian clinical reports describe use in anxiety and in cognitive or attention-related complaints. Most of this evidence comes from studies conducted by the same research groups that developed the peptide. Independent replication in other countries remains limited, and no major Western regulatory agency has approved the compound for any indication. The gap between local reports and external verification is a recurring point in discussions of the peptide.
| Property | Value | Notes |
|---|---|---|
| Route studied | Intranasal | Predominant route in published reports |
| Circulation stability | Short, minutes scale | Peptidases cleave it; the tail slows the process |
| Analytical method | RP-HPLC with mass spectrometry | Used for identity and purity assessment |
| Reported outcome domains | Anxiety and cognitive measures | Derived from small, mostly regional trials |
| Regulatory status | Marketed in Russia | Availability outside that market is limited |
Selank is a hydrophilic peptide and dissolves readily in water and in aqueous buffers. The lyophilised powder is typically a white to off-white solid. Because short peptides are prone to hydrolysis and oxidation, handling benefits from limiting exposure to heat, moisture and strong light. Working solutions are commonly prepared in sterile water or saline, and repeated freeze-thaw cycles are avoided to reduce aggregation and loss of activity. These practices reflect general laboratory convention rather than published stability specifications.
Dry powder is normally held at -20 degrees Celsius or lower, in a sealed container with desiccant and protection from light. Reconstituted solutions are usually kept at 2 to 8 degrees Celsius for short periods and frozen for longer ones. Proline residues at several positions are generally associated with some resistance to peptidase attack, but chemical stability still declines at neutral to alkaline pH and at elevated temperature. Exact shelf-life figures are product-specific and are not standardised across suppliers.
Lyophilized selank is normally supplied as a dry powder and is considered stable for extended periods when kept cold and dry. Moisture uptake is the main practical threat, because absorbed water promotes both hydrolysis and aggregation in the solid state. Vials are usually warmed to room temperature before opening so that condensation does not form on the powder. Supplier documentation commonly specifies -20 °C for routine storage, with -80 °C used for material intended to be archived for years.
Once dissolved, the peptide is markedly less stable than the dry powder. Aqueous solutions are subject to backbone hydrolysis and to microbial growth when they are handled without sterile technique. Buffered solutions near neutral pH are common for short-term laboratory work, while acidic conditions are sometimes used to improve solubility. Analytical laboratories generally prepare working solutions fresh rather than storing them, and a residual water film left in a reopened vial can seed degradation even when the container appears dry.
Selank is studied chiefly as an animal-model anxiolytic with proposed secondary effects on memory and immune signaling. Reported mechanisms include modulation of the GABA-A receptor complex, inhibition of enkephalin-degrading enzymes, and shifts in monoamine turnover within limbic structures. Some experiments describe increased expression of brain-derived neurotrophic factor in the hippocampus after repeated dosing. No single molecular target has been confirmed, and the peptide does not bind any receptor with the selectivity typical of a conventional small-molecule drug. Mechanism therefore remains a set of hypotheses rather than an established pathway.
Laboratory work relies on standard behavioral paradigms. Rodents are tested in the elevated plus maze, open field, and passive avoidance tasks, with outcomes compared against diazepam or vehicle controls. Intranasal dosing is used most often because it bypasses first-pass metabolism, though intraperitoneal and intravenous routes also appear in published protocols. Biochemical endpoints include tissue BDNF concentrations, cytokine levels, and monoamine metabolites. Human data are limited to small Russian trials reporting reduced anxiety scores; most were not prospectively registered, and few employed independent outcome assessment.
=== Antivenom === Until the advent of antivenom, bites from some species of snake were almost universally fatal. Despite huge advances in emergency therapy, antivenom is often still the only effective treatment for envenomation. The first antivenom was developed in 1895 by French physician Albert Calmette for the treatment of Indian cobra bites. Antivenom is made by injecting a small amount of venom into an animal (usually a horse or sheep) to initiate an immune system response. The resulting antibodies are then harvested from the animal's blood. Antivenom is injected into the person intravenously, and works by binding to and neutralizing venom enzymes. It cannot undo the damage already caused by venom, so antivenom treatment should be sought as soon as possible. Modern antivenoms are usually polyvalent, making them effective against the venom of numerous snake species. Pharmaceutical companies that produce antivenom target their products against the species native to a particular area. The availability of antivenom is a major concern in some areas, including most of Africa, due to economic reasons (antivenom crisis). In Sub-Saharan Africa, the efficacy of antivenom is often poorly characterised and some of the few available products have even been found to lack effectiveness. Although some people may develop serious adverse reactions to antivenom, such as anaphylaxis, in emergency situations this is usually treatable in a hospital setting and hence the benefit outweighs the potential consequences of not using antivenom.
Polysaccharide peptide (PSP) is a protein-bound polysaccharide extracted from the edible mushroom Coriolus versicolor. PSP is currently in the animal-testing phase of research in many countries for use as an anti-tumor drug. It appears to work as a biological response modifier (BRM), enhancing the body's own use of macrophages and T-lymphocytes, rather than directly attacking any tumors. Polysaccharide krestin (PSK) was first isolated in Japan in the late 1960s while PSP was isolated about 1983 in China. Each compound has shown remarkable anticancer properties with few side effects. By 1987 PSK accounted for more than 25% of total national expenditure for anticancer agents in Japan.
=== Development === The mesenchyme originates from the mesoderm. From the mesoderm, the mesenchyme appears as an embryologically primitive "soup". This "soup" exists as a combination of the mesenchymal cells plus serous fluid plus the many different tissue proteins. Serous fluid is typically stocked with the many serous elements, such as sodium and chloride. The mesenchyme develops into the tissues of the lymphatic and circulatory systems, as well as the musculoskeletal system. This latter system is characterized as connective tissues throughout the body, such as bone, and cartilage. A malignant cancer of mesenchymal cells is a type of sarcoma.
Sources: en.wikipedia.org
== Structure == Three distinct fiber types have been identified within the dermis: oxytalan, elaunin, and elastic fibers. The most superficial of these, the oxytalan fibers, are extremely slender and oriented perpendicularly to the dermoepidermal junction. They arise from a plexus exhibiting the staining properties of elaunin fibers, which in turn are contiguous with the thicker elastic fibers of the reticular dermis. Electron microscopy shows that oxytalan fibers consist of bundles of tubular microfibrils measuring approximately 10–12 nm in diameter. In deeper dermal layers, these bundles contain a central amorphous substance. Elaunin fibers contain only small amounts of this amorphous material, whereas in elastic fibers it is abundant and densely compacted. The structure of Elaunin fibers allows for repeated stretching or pressure because they are made up of microfibrils and small amounts of elastic fibers (Sawada et al, 2006.) These elaunin fibers have moderate tissue elasticity and plays an important role by allowing tissues such as skin and mucosa to stretch during everyday movements without becoming permanently damaged. Additionally, the fibers support blood vessels by maintaining the shape of vessel lumen, especially during sudden or repeated changes in pressure. The flexibility of elaunin fibers allows for a certain level of stretch that is still strong enough to support moving tissues but does not recoil like fully developed elastic fibers do.
Sunak refuses to rule out a general election in July following speculation of a summer election. 29 April – 2024 Scottish government crisis: First Minister, Humza Yousaf, announces he will resign as both leader of the SNP and first minister of Scotland when his successor is chosen. The UK government launches a 12 week consultation process on changes to Personal Independence Payment benefits. MPs debates assisted dying after a petition started by Dame Esther Rantzen was signed by 200,000 people, triggering a parliamentary debate. SDLP Councillor Lilian Seenoi-Barr is set to become Northern Ireland's first black mayor after being selected as the next first citizen of Derry City and Strabane District Council. 30 April – Officials at Holyrood confirm that Labour's motion of no confidence in the Scottish Government will be voted on by MSPs the next day. Former England cricketer Monty Panesar is announced as the Workers Party of Britain candidate for Ealing Southall.
Amphetamine-Dextroamphetamine is known to hamper appetite. Amphetamine-Dextroamphetamine is used to treat Attention deficit hyperactivity disorder (ADHD) and is usually under the trade name "Adderall" or "Mydayis". Amphetamine sulfate (also known as amfetamine) – US FDA-approved for the treatment of exogenous obesity under the brand name "Evekeo". Methylphenidate Cocaine Caffeine Glucomannan Leptin Lisdexamfetamine - US FDA approved for the treatment of binge-eating disorder in adults under the brand name "Vyvanse". Methamphetamine hydrochloride – USFDA-approved for the treatment of obesity (as a short-term) under the brand name "Desoxyn". Nicotine Liraglutide as brand name Saxenda Semaglutide (brand name Ozempic/Wegovy) GLP-1 agonist Tirzepatide (Brand Name Mounjaro, Zepbound) Metformin Opiates/opioids such as heroin, morphine, codeine, oxycodone, fentanyl, etc. Anti-obesity medication
Sources: en.wikipedia.org
Reports describe effects on GABA-A receptor expression, monoamine turnover, and neurotrophic factor levels. These are proposed mechanisms drawn mainly from animal models. No single molecular target has been established.
Intranasal delivery is the route described in most published work. It is used because the peptide is degraded quickly once it reaches circulation. Direct evidence of brain penetration in humans is lacking.
Most trials are small, regionally concentrated, and often lack rigorous blinding or placebo control. Independent replication is limited. Reviews in English generally rate the evidence as preliminary.
Selank is a synthetic peptide made of seven amino acids. It is modeled on tuftsin, a natural tetrapeptide, with an added three-residue tail. It is not a small-molecule drug.